(株)ティムス
株価チャート
2026/07/15 更新株価トレンド
2026/07/15 更新株価・取引詳細
2026/07/15 更新株価
取引
財務パフォーマンス
2026/07/12 更新売上・利益
利益率
キャッシュフロー
財務健全性
| 2022 | |
|---|---|
| 損益計算書 | |
| 売上高 | ¥19億 |
| 売上総利益 | - |
| 営業利益 | ¥11億 |
| 経常利益 | ¥11億 |
| 当期純利益 | ¥11億 |
| EPS | ¥53.36 |
| 営業利益率 | 58.34% |
| 貸借対照表 | |
| 総資産 | ¥27億 |
| 純資産 | ¥25億 |
| 総負債 | ¥3億 |
| 現金 | ¥26億 |
| 有利子負債 | - |
| 自己資本比率 | 89.53% |
| D/Eレシオ | 0.00 |
| キャッシュフロー | |
| 営業CF | ¥13億 |
| 投資CF | -¥0億 |
| 財務CF | ¥2億 |
| フリーCF | ¥13億 |
| 効率性 | |
| ROE | 43.90% |
| ROA | 39.30% |
最新ニュース (5件)
(株)ティムス【4891】：決算情報 - Yahoo!ファイナンス ↗
ティムス、1-3月期(1Q)経常は2億円の赤字で着地 - 株探 ↗
企業情報
会社概要
TMS Co., Ltd. engages in the research and development, manufacture, and sale of drug products, quasi-drugs, drug substances, medical devices, and medical commodities. The company is developing TMS-007, a stachybotrys microspora triprenyl phenol (SMTP) congener with prothrombolytic and anti-inflammatory/antioxidative activities, which has completed Phase 2a clinical trials for acute ischemic stroke treatment; and TMS-008, an SMTP congener with anti-inflammatory/antioxidative activities under nonclinical development for inflammatory complications, such as acute kidney injury and cancer cachexia. It is also developing TMS-009, a product candidate in preclinical development. In addition, the company has a collaboration with Hokkaido University to evaluate the potential of the drug candidate compounds as novel drugs. TMS Co., Ltd. was incorporated in 2005 and is headquartered in Fuchu, Japan.
